Hologic, Inc. $HOLX Holdings Cut by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 69.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,063 shares of the medical equipment provider’s stock after selling 20,734 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Hologic were worth $612,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HOLX. The Manufacturers Life Insurance Company increased its position in Hologic by 294.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after purchasing an additional 8,227,318 shares during the last quarter. Invesco Ltd. raised its position in Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after acquiring an additional 3,505,828 shares in the last quarter. Norges Bank acquired a new stake in Hologic in the second quarter valued at approximately $180,055,000. Allspring Global Investments Holdings LLC grew its position in Hologic by 473.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock worth $111,180,000 after acquiring an additional 1,405,085 shares in the last quarter. Finally, Black Creek Investment Management Inc. increased its stake in shares of Hologic by 26.1% during the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock worth $262,453,000 after purchasing an additional 832,444 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HOLX has been the subject of several analyst reports. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Stephens lowered Hologic from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $78.00 to $76.00 in a report on Wednesday, October 22nd. BNP Paribas Exane downgraded Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective on the stock. in a research note on Friday, November 21st. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $78.00 target price on shares of Hologic in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Stock Performance

HOLX opened at $74.81 on Friday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The stock’s 50 day moving average price is $74.87 and its two-hundred day moving average price is $71.27. The firm has a market capitalization of $16.70 billion, a P/E ratio of 31.17, a price-to-earnings-growth ratio of 2.23 and a beta of 0.72. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.36.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.87 earnings per share. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.